Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
Sponsor: Changhai Hospital
Summary
Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.
Official title: Impact of Immediate Cisplatin/Gemcitabine Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer: an Open-label, Single-arm, Prospective Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2024-06-01
Completion Date
2028-06-01
Last Updated
2025-03-21
Healthy Volunteers
No
Conditions
Interventions
Immediate postoperative chemotherapy
Systemic chemotherapy with cisplatin/gemcitabine intravenous infusion within 24 hours after TURBT
Locations (1)
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, China